Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma
AbstractWe herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of plateletderived growth factor receptor beta expression in our case may have a crucial role.
Google ScholarGoogle Scholar
- Abstract views: 734
- PDF: 532
- HTML: 172
Copyright (c) 2012 Chihiro Kawakami, Akiko Inoue, Kimitaka Takitani, Motomu Tsuji, Kimiko Wakai, Hiroshi Tamai
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.